{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:16:34Z","timestamp":1789676194681,"version":"4.0.1"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008728","name":"Japan Research Foundation for Clinical Pharmacology","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008728","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.eplepsyres.2016.12.014","type":"journal-article","created":{"date-parts":[[2016,12,26]],"date-time":"2016-12-26T14:01:43Z","timestamp":1482760903000},"page":"7-12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Add-on stiripentol elevates serum valproate levels in patients with or without concomitant topiramate therapy"],"prefix":"10.1016","volume":"130","author":[{"given":"Toshihiro","family":"Jogamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsumasa","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsumi","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukitoshi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushi","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Ohtsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2016.12.014_bib0005","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(00)03157-3","article-title":"Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebocontrolled syndrome-dedicated trial. STICLO study group","volume":"356","author":"Chiron","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.eplepsyres.2016.12.014_bib0010","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2147\/ODRR.S47619","article-title":"Stiripentol for the treatment of Dravet syndrome","volume":"4","author":"Chiron","year":"2014","journal-title":"J. Orphan Drugs: Res. Rev."},{"key":"10.1016\/j.eplepsyres.2016.12.014_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2016.05.012","article-title":"A french cohort cross-sectional study","author":"De Liso","year":"2016","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2016.12.014_bib0020","series-title":"Epileptic Syndromes in Infancy, Childhood and Adolescence.","first-page":"89","article-title":"Severe myoclonic epilepsy in infancy (Dravet syndrome)","author":"Dravet","year":"2005"},{"key":"10.1016\/j.eplepsyres.2016.12.014_bib0025","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1124\/dmd.105.007237","article-title":"In vitro and in vivo inhibitory effect of stiripentol on clobazam metabolism","volume":"34","author":"Giraud","year":"2006","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.eplepsyres.2016.12.014_bib0030","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/j.1528-1167.2007.01475.x","article-title":"A screening test for the prediction of Dravet syndrome before one year of age","volume":"49","author":"Hattori","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2016.12.014_bib0035","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.eplepsyres.2014.02.008","article-title":"Effectiveness of add-on stiripentol to clobazam and valproate in Japanese patients with Dravet syndrome: additional supportive evidence","volume":"108","author":"Inoue","year":"2014","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2016.12.014_bib0040","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.eplepsyres.2015.03.012","article-title":"Long-term safety and efficacy of stiripentol for the treatment of Dravet syndrome: a multicenter, open-label study in Japan","volume":"113","author":"Inoue","year":"2015","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2016.12.014_bib0045","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s00228-009-0712-x","article-title":"Effects of CYP2C19 and CYP2C9 genotypes on pharmacokinetic variability of valproic acid in Chinese epileptic patients: nonlinear mixed-effect modeling","volume":"65","author":"Jiang","year":"2009","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2016.12.014_bib0050","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.braindev.2014.04.003","article-title":"Effect of CYP2C19 polymorphisms on stiripentol administration in Japanese cases of Dravet syndrome","volume":"37","author":"Kouga","year":"2015","journal-title":"Brain Dev."},{"key":"10.1016\/j.eplepsyres.2016.12.014_bib0055","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/clpt.1990.144","article-title":"Effects of polytherapy with phenytoin, carbamazepine, and stiripentol on formation of 4-en-valproate, a hepatotoxic metabolite of valproic acid","volume":"48","author":"Levy","year":"1990","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.eplepsyres.2016.12.014_bib0060","first-page":"554","article-title":"An investigation on the borderland of severe myoclonic epilepsy in infancy","volume":"42","author":"Ogino","year":"1988","journal-title":"Jpn. J. Psychiatry Neurol."},{"key":"10.1016\/j.eplepsyres.2016.12.014_bib0065","series-title":"Antiepileptic Drug Interactions\u2014a Clinical Guide","first-page":"163","article-title":"Topiramate","year":"2013"},{"key":"10.1016\/j.eplepsyres.2016.12.014_bib0070","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1111\/j.1528-1157.1999.tb02048.x","article-title":"Stiripentol: efficacy and tolerability in children with epilepsy","volume":"40","author":"Perez","year":"1999","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2016.12.014_bib0075","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s40263-012-0004-3","article-title":"Stiripentol: in severe myoclonic epilepsy of infancy (Dravet syndrome)","volume":"26","author":"Plosker","year":"2012","journal-title":"CNS Drugs"},{"key":"10.1016\/j.eplepsyres.2016.12.014_bib0080","doi-asserted-by":"crossref","first-page":"470","DOI":"10.2165\/00003088-199631060-00005","article-title":"Pharmacokinetic interactions between antiepileptic drugs. Clinical considerations","volume":"31","author":"Riva","year":"1996","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.eplepsyres.2016.12.014_bib0085","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1046\/j.1528-1157.2002.41701.x","article-title":"Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients","volume":"43","author":"Sachdeo","year":"2002","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2016.12.014_bib0090","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/ane.12403","article-title":"Stiripentol for the treatment of super-refractory status epilepticus","volume":"132","author":"Strzelczyk","year":"2015","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.eplepsyres.2016.12.014_bib0095","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S0009-9236(97)90044-8","article-title":"Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: in vitro and in vivo comparison and calculation of in vivo inhibition constants","volume":"62","author":"Tran","year":"1997","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.eplepsyres.2016.12.014_bib0100","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1111\/epi.13057","article-title":"Summary of recommendations for the management of infantile seizures: task Force Report for the ILAE Commission of Pediatrics","volume":"56","author":"Wilmshurst","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2016.12.014_bib0105","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/FTD.0b013e318283b49a","article-title":"Influence of CYP2C19 polymorphism and concomitant antiepileptic drugs on serum clobazam and N-desmethyl clobazam concentrations in patients with epilepsy","volume":"35","author":"Yamamoto","year":"2013","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.eplepsyres.2016.12.014_bib0110","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1007\/s00228-014-1719-5","article-title":"Impact of cytochrome P450 inducers with or without inhibitors on the serum clobazam level in patients with antiepileptic polypharmacy","volume":"70","author":"Yamamoto","year":"2014","journal-title":"Eur. J. Clin. Pharmacol."}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121116304041?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121116304041?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:35:52Z","timestamp":1760276152000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121116304041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":22,"alternative-id":["S0920121116304041"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2016.12.014","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Add-on stiripentol elevates serum valproate levels in patients with or without concomitant topiramate therapy","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2016.12.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}